Sanofi-Aventis settles federal lawsuit for $182.8 million

Share this article:

Sanofi-Aventis agreed to pay $182.8 million plus interest to resolve lawsuits under the federal Claims Act relating to Anzemet and involving predecessor company Aventis Pharmaceuticals.

The US government alleged that Aventis inflated the price for Anzemet, a drug used in conjunction with other cancer treatments, causing the government to overpay for Anzemet for a seven years, between 1997 through 2004.

Anzemet was introduced in 1997 and is provided to cancer patients to prevent nausea and vomiting that can accompany some types of chemotherapy.

Sanofi-Aventis "has decided to resolve this legacy matter through this settlement, without admitting any wrongdoing," the company said in a statement.

Also as part of the settlement deal, Sanofi-Aventis' US pharmaceutical subsidiary
has entered into a five-year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...